Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cutaneous Malignancies in Patients Treated With Psoralen Photochemotherapy (PUVA) for Vitiligo

Cutaneous Malignancies in Patients Treated With Psoralen Photochemotherapy (PUVA) for Vitiligo Abstract Vitiligo is an acquired, sometimes familial, depigmentation disorder of the skin and hair. Oral or topical psoralen photochemotherapy (PUVA) is the most popular and efficacious treatment currently available in the United States for repigmentation of vitiliginous patches.1 However, the long-term safety of this treatment is still under investigation, and further studies are warranted. There are limited published studies examining the long-term risk in patients with vitiligo who have been treated with oral PUVA therapy. We found no published studies examining the long-term risk in patients with vitiligo treated with topical PUVA therapy. A study of 59 patients with vitiligo, who received oral PUVA therapy from 1972 through 1986, reported no incidence of skin cancers, actinic keratoses, or lentigines.2 Likewise, a 1984 study examining 596 East Indian patients with vitiligo, who were treated with oral psoralen and sunlight (PUVASOL), reported that no increased risk of cutaneous carcinoma was apparent References 1. Nordlund JJ, Halder RM, Grimes P. Management of vitiligo . Dermatol Clin . 1993;11:27-33.Crossref 2. Wildfang IL,Jacobsen FK, Thestrup-Pedersen K. PUVA treatment of vitiligo: a retrospective study of 59 patients . Acta Derm Venereol (Stockh) . 1992;72: 305-306. 3. Harrist TJ, Pathak MA, Mosher DB, et al. Chronic cutaneous effects of longterm psoralen and ultraviolet radiation therapy in patients with vitiligo . Natl Cancer Inst Monogr. 1984;66:191-196. 4. Haider RM. Topical PUVA therapy for vitiligo . Dermatol Nurs. 1991;3:178-180. 5. Stern RS, Lange R. Nonmelanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment . J Invest Dermatol. 1988;91: 120-124.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Cutaneous Malignancies in Patients Treated With Psoralen Photochemotherapy (PUVA) for Vitiligo

Loading next page...
 
/lp/american-medical-association/cutaneous-malignancies-in-patients-treated-with-psoralen-NxI8mIMqxD
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1995.01690180114025
Publisher site
See Article on Publisher Site

Abstract

Abstract Vitiligo is an acquired, sometimes familial, depigmentation disorder of the skin and hair. Oral or topical psoralen photochemotherapy (PUVA) is the most popular and efficacious treatment currently available in the United States for repigmentation of vitiliginous patches.1 However, the long-term safety of this treatment is still under investigation, and further studies are warranted. There are limited published studies examining the long-term risk in patients with vitiligo who have been treated with oral PUVA therapy. We found no published studies examining the long-term risk in patients with vitiligo treated with topical PUVA therapy. A study of 59 patients with vitiligo, who received oral PUVA therapy from 1972 through 1986, reported no incidence of skin cancers, actinic keratoses, or lentigines.2 Likewise, a 1984 study examining 596 East Indian patients with vitiligo, who were treated with oral psoralen and sunlight (PUVASOL), reported that no increased risk of cutaneous carcinoma was apparent References 1. Nordlund JJ, Halder RM, Grimes P. Management of vitiligo . Dermatol Clin . 1993;11:27-33.Crossref 2. Wildfang IL,Jacobsen FK, Thestrup-Pedersen K. PUVA treatment of vitiligo: a retrospective study of 59 patients . Acta Derm Venereol (Stockh) . 1992;72: 305-306. 3. Harrist TJ, Pathak MA, Mosher DB, et al. Chronic cutaneous effects of longterm psoralen and ultraviolet radiation therapy in patients with vitiligo . Natl Cancer Inst Monogr. 1984;66:191-196. 4. Haider RM. Topical PUVA therapy for vitiligo . Dermatol Nurs. 1991;3:178-180. 5. Stern RS, Lange R. Nonmelanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment . J Invest Dermatol. 1988;91: 120-124.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Jun 1, 1995

References